Intensity Therapeutics INTS
NASDAQ INTS
$3.14 -0.14 (-4.14%)
As of: Oct 21, 2026 · 3:44 PM EDT

Intensity Therapeutics (INTS) Other Non-Current Liabilities (2022 - 2024)

Updated

Intensity Therapeutics' Other Non-Current Liabilities was $36,000 in Q1 2024, unchanged from the prior quarter.

Analysis

Intensity Therapeutics (INTS) Other Non-Current Liabilities (2022 - 2024) Analysis & Trends

From Q4 2022 onward, Intensity Therapeutics has reported Other Non-Current Liabilities for 4 quarters.

  • In earlier years, Other Non-Current Liabilities was $36,000 in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Intensity Therapeutics 8.51 Mn -30.26 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2024 36,000.00
Dec 31, 2023 36,000.00
Sep 30, 2023 36,000.00
Dec 31, 2022 36,000.00
API Access

Intensity Therapeutics Other Non-Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-non-current-liabilities&ticker=INTS&period=max&api_key=YOUR_API_KEY